Today: 7 February 2026
Subscribe
Browse Category

SWX:ROG News 21 November 2025 - 1 February 2026

Roche stock price ends week higher — dividend vote and 2026 outlook set the tone for Monday

Roche stock price ends week higher — dividend vote and 2026 outlook set the tone for Monday

Roche shares closed Friday up 1.1% at CHF 350.70 after reporting 2025 sales of CHF 61.5 billion, a 7% rise at constant exchange rates. The board proposed a CHF 9.80 dividend. The company forecasts mid single-digit sales growth for 2026. Investors await updates on dividends in March and the next company briefing on April 23.
1 February 2026
·····
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
········
Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche participation shares closed Friday at 348.10 Swiss francs, up 0.06% and near a 52-week high. The company will report full-year 2025 results before the Swiss market opens on Jan. 29, followed by a management webcast. Investors are watching for 2026 guidance and updates on drug launches and diagnostics demand. The Swiss Market Index fell 0.61% Friday.
25 January 2026
·····
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·······
Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom

Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom

Zurich, Jan 18, 2026, 17:32 CET — Market closed Roche Holding Ltd’s non-voting shares ended Friday up 0.93%, closing at 348.90 Swiss francs. The stock has remained within a narrow band heading into Monday’s session. (MarketScreener) Goldman Sachs upgraded Roche from “sell” to “neutral” and boosted its 12-month price target to 365 Swiss francs, up from 260. The bank highlighted a smoother slate of clinical milestones expected in 2026, following late-2025 trial results. It singled out fenebrutinib, Roche’s experimental multiple sclerosis treatment, and the breast cancer drug giredestrant as key growth drivers. Despite the optimism, Goldman Sachs held back on
18 January 2026
·····
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

NEW YORK, Jan 13, 2026, 12:18 EST — Regular session Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech. (https://www.reuters.com/markets/companies/GPCR.O) This shift is significant as major drugmakers ramp up their push for obesity pills. Investors have been flocking to smaller, riskier companies poised to gain if these treatments capture a larger slice of the market than previously anticipated. At this week’s J.P. Morgan Healthcare Conference in San Francisco, Novo Nordisk said pills could account
13 January 2026
······
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

ZURICH, Jan 11, 2026, 17:40 CET — The market has closed. Roche Holding shares rose 0.4% on Friday following news that China’s MediLink Therapeutics inked a licensing deal with the Swiss pharma giant for an experimental cancer drug. The stock closed at 340.80 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The deal underscores how big pharma continues to invest heavily in oncology pipelines, despite investor calls for more defined revenue prospects. Antibody-drug conjugates, or ADCs, remain a standout area in cancer R&D — leveraging antibodies to carry lethal agents directly to tumors. Timing is key for Roche. Shares are
11 January 2026
·····
Swiss Stock Market Outlook Today (9 December 2025): Roche Catalysts, SNB Rate Bets and Fed Jitters Set the Tone

Swiss Stock Market Outlook Today (9 December 2025): Roche Catalysts, SNB Rate Bets and Fed Jitters Set the Tone

Zurich’s stock market is heading into Tuesday’s session with the Swiss Market Index (SMI) hovering just under the symbolic 13,000 level, as investors juggle a powerful mix of bullish news from Roche, cautious analyst calls on financials and industrials, and a high‑stakes week for central banks led by the Swiss National Bank (SNB) and the U.S. Federal Reserve. Below is a structured rundown of what you need to know before the SIX Swiss Exchange opens today. 1. Where the Swiss Market Index Stands Before the Bell Monday’s close: SMI flirts with 13,000 Pre‑market indication: slightly softer start Taken together, the signals suggest a broadly flat
9 December 2025
····
Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

Swiss Stock Market Today, 21 November 2025: SMI Holds Near Flat as Tech Slides and Defensives Lift Zurich

The Swiss stock market opened under pressure on Friday but quickly stabilised, with the Swiss Market Index (SMI) hovering just above the previous day’s close as investors rotated out of high‑flying tech names and into defensive blue chips. By mid‑morning in Zurich, the SMI was trading around 12,553 points, roughly 0.1% higher than Thursday’s close of 12,543, according to intraday data from cash.ch and MarketScreener. cash.ch+2MarketScreener UK+2 That modest gain came after futures had pointed to a drop of nearly three‑quarters of a percent earlier in the morning. finanzen.ch Global risk aversion, Fed uncertainty and a violent reversal in US
21 November 2025
·······

Stock Market Today

iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

7 February 2026
Hongkong Land shares fell 4.2% to US$8.18 in Singapore on Friday after the company disclosed a buyback of 170,000 shares at US$8.5252 each on Feb. 5, with plans to cancel them. The drop followed a volatile week marked by a new Singapore real estate fund launch and an expanded buyback programme. Investors are watching for the group’s annual results on March 5.
Go toTop